ArticleCanada communicable disease report = Releve des maladies transmissibles au Canada2025
Summary of the mpox outbreak in Canada, April 28-December 31, 2022.
Article in Canada communicable disease report = Releve des maladies transmissibles au Canada, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Surveillance of Mpox Cases in Mexico: Epidemiological Patterns During the 2022-2023 National Outbreak.Diseases (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Mpox is an infectious disease caused by the monkeypox virus (MPXV), closely related to the virus that causes smallpox. In May 2022, cases of mpox were reported in previously non-endemic countries including Canada. Objective: To summarize the epidemiology of the mpox outbreak in Canada, as well as key public health response activities, between April and December 2022. Methods: The Public Health Agency of Canada (PHAC) worked closely with local, provincial and territorial public health authorities to develop national case investigation and reporting tools, including national case definitions for confirmed and probable mpox cases. Based on de-identified case data submitted to PHAC, patterns and trends were examined, including the distribution of cases by sociodemographic, clinical and transmission factors. Results: Overall, 1,474 mpox cases (1,396 confirmed, 78 probable) were reported to PHAC. All reported cases were associated with MPXV clade IIb. Mpox disproportionately affected gay, bisexual and other men who have sex with men (80.0%) and those between 20-49 years of age (86.0%). Available data suggests that the most likely mode of disease acquisition was through sexual contact, with limited evidence on other possible modes of transmission. Some cases were hospitalized (3.0%); however, there were no mpox-related deaths in Canada. Conclusion: Rapid coordination and surveillance activities supported the timely implementation of tailored interventions, including the procurement and distribution of vaccines. These actions, coupled with vaccination uptake and behavioural changes, contributed to reducing transmission and health impacts of mpox on the Canadian population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.